Trial reportCancer prevention research (Philadelphia, Pa.)2017
A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer.
Trial report in Cancer prevention research (Philadelphia, Pa.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Impact of Nutritional Supplements and Antioxidants in the Treatment of Breast Cancer: A Systematic Review.Nutrients · 2026Pooled it
- Dietary Patterns, Dietary Interventions, and Mammographic Breast Density: A Systematic Literature Review.Nutrients · 2022Pooled it
- Green tea (Camellia sinensis) for the prevention of cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Green Tea Consumption and Risk of Breast Cancer and Recurrence-A Systematic Review and Meta-Analysis of Observational Studies.Nutrients · 2018Pooled it
- Trial
- A Randomized Controlled Trial of Soy Isoflavone Intake on Mammographic Density among Malaysian Women.Nutrients · 2023Trial
- Modifiable and Nonmodifiable Risk Factors for Breast Cancer: A Comprehensive Scoping Review.International journal of breast cancer · 2026Review
- Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications.Cancer pathogenesis and therapy · 2025Review
- The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.Frontiers in immunology · 2024Review
- Comparative Anticancer Potential of Green Tea Extract and Epigallocatechin-3-gallate on Breast Cancer Spheroids.Foods (Basel, Switzerland) · 2023Article
- Exploration of plasma adiponectin, leptin, andJournal of nutritional science · 2023Article
- Extracts of Common Vegetables Inhibit the Growth of Ovary Cancer Cells.Foods (Basel, Switzerland) · 2022Article
- Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome.Cancers · 2022Review
- Green Tea Epigallocatechin-3-Gallate Regulates Autophagy in Male and Female Reproductive Cancer.Frontiers in pharmacology · 2022Review
- Natural biomolecules and derivatives as anticancer immunomodulatory agents.Frontiers in immunology · 2022Review
- Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy.Frontiers in pharmacology · 2022Review
- Molecular Targets of Natural Compounds with Anti-Cancer Properties.International journal of molecular sciences · 2021Review
- Article
- Antioxidants for the Treatment of Breast Cancer: Are We There Yet?Antioxidants (Basel, Switzerland) · 2021Review
- AhR and Cancer: From Gene Profiling to Targeted Therapy.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
Epidemiologic and animal studies suggest a protective role of green tea against breast cancer. However, the underlying mechanism is not understood. We conducted a randomized, double-blinded, placebo-controlled phase II clinical trial to investigate whether supplementation with green tea extract (GTE) modifies mammographic density (MD), as a potential mechanism, involving 1,075 healthy postmenopausal women. Women assigned to the treatment arm consumed daily 4 decaffeinated GTE capsules containing 1,315 mg total catechins, including 843 mg epigallocatechin-3-gallate (EGCG) for 12 months. A computer-assisted method (Madena) was used to assess MD in digital mammograms at baseline and month 12 time points in 932 completers (462 in GTE and 470 in placebo). GTE supplementation for 12 months did not significantly change percent MD (PMD) or absolute MD in all women. In younger women (50-55 years), GTE supplementation significantly reduced PMD by 4.40% as compared with the placebo with a 1.02% PMD increase from pre- to postintervention (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.